BOC Sciences' Burosumab monoclonal antibody.
Description
Burosumab is a human monoclonal antibody targeting the phosphaturic hormone fibroblast growth factor 23 (FGF23). Burosumab is currently in a phase III clinical trial for the treatment of patients with X-linked hypophosphatemia